Konference: 2006 48th ASH Annual Meeting - účast ČR
Kategorie:
Maligní lymfomy a leukémie
Téma: Publikace ve sborníku
Číslo abstraktu: 4128
Autoři: MUDr. Veronika Fiamoli, Ph.D.; MUDr. Jan Blatný, Ph.D.; MUDr. Ondřej Zapletal, Ph.D.; MUDr. Světlana Köhlerová; prof. MUDr. Miroslav Penka, CSc.
Incidence of the thrombosis is age dependent with the lowest risk
is in the childhood. Children mostly suffer from vein thrombosis
(DVT/ PE). Occurrence of thrombosis in children is 0,07/ 10 000,
among hospitalized children is higher 3,5/ 10 000. In comparison
with adults, these numbers are very low. LMWH is preferred in the
treatment of DVT in children. UFH is used as second choice
medication. LMWH is widely used in prevention of recurrence of DVT
and sometimes it substitutes (especially in very young children)
vitamin K antagonists. The most frequent form of application of
LMWH is via subcutaneous injection. A few articles can be found in
literature about treatment by intravenous continuous infusion in
infants and in several cases in older children. The treatment by
continuous infusion has certain advantages, especially for
hospitalized patient with permanent i.v. access (painless, shorter
half-life consecutively lower risk of bleeding, easier control). We
present group of 27 children with DVT, who were treated with LMWH
for first thrombosis from 2003 till 2005. We did the screening of
thrombophilia in all of those children. We found FVleiden
heterozygous in 38,1%, FII G2021OA heterozygous in 4,76, inherited
deficiency of AT in 14,29%, BCP in 9,52 % and CVL was inserted in
52,38% of our patients.All patients had at least one of the risk
factors of thrombophilia. We started to treat all patients with
LMWH and the dose was adjusted to reach the level of antiXa between
0,5-1 IU/ml. We treated 6 patients (22,22%) by subcutaneous
injection (average LMWH dose 215,54IU/kg/d) and 21 patients
(77,78%) by continuous infusion (average dose 254,94IU/kg/d).
Duration of the treatment was modified in accordance with the
course of thrombosis (monitored by Doppler ultrasound with
compression), but it went on for at least 7 days and was followed
by the prophylaxis with LMWH or vitamin K antagonists. The
treatment with LMWH (both i.v. or s.c.) lead to recanalisation of
the vein in 26 cases (96,29%), 58% of them without any residue or
mural thrombosis. We did not notice any bleeding as adverse event
of the treatment in our patients.We would like to point out that
treatment of DVT with continuous infusion of LMWH in children might
be efficient and safe alternative of to s.c. application in certain
circumstances. When administered by continuous infusion, LMWH has
shorter half-life and it could be useful especially in hospitalized
children and in children who are endangered by risk of bleeding
complications.
Datum přednesení příspěvku: 9. 12. 2006